Use of cannabidiol in the treatment of autism, review of the literature and future perspectives




Autism Spectrum Disorder; Cannabis sativa; Pharmacological treatment; Receptors.


Autism Spectrum Disorders (ASD) are considered a multifactorial disease, being associated with genetic and non-genetic causes with a predominance of development in early childhood and that compromises the cognitive, social and affective spheres, in addition to physical growth itself. There are no specific medications for autism and several medications are used to alleviate the symptoms associated with ASD, in addition there is much discussion about the use of cannabidiol. This work is a systematic review of the literature with the aim of understanding more about the use of cannabidiol to help treat patients with ASD. The results found demonstrate a strong relationship between TEA and the endocannabinoid system, especially in the CB1 and CB2 receptors. Most of the works show that the use of cannabidiol brought more benefits than side effects or adverse reactions, acting mainly in the improvement of the signs and symptoms of ASD. Therefore, it is concluded that it is of great importance to carry out more studies to clarify points that are still obscure in the use of cannabidiol in the treatment of ASD.


Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022). An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics, 19(1), 248–262.

Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., Shmueli, D., Golan, D., & Castellanos, F. X. (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism, 12(1), 1–11.

Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019). Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Scientific Reports, 9(1), 1–7.

Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., Koren, G., & Berkovitch, M. (2019). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and Co-morbidities. Frontiers in Pharmacology, 9(JAN), 1–5.

Chayasirisobhon, S. (2019). Cannabis and neuropsychiatric disorders: An updated review. Acta Neurologica Taiwanica, 28(2), 27–39.

SIlva Junior, E. A. (2020). Avaliação Da Eficácia E Segurança Do Extrato De Cannabis Rico Em Canabidiol Em Crianças Com O Transtorno Do Espectro Autista: “Ensaio Clínico Randomizado, Duplo-Cego E Placebo Controlado.” 149.

Ferreira, C. I. R. (2020). Etiologia e Fisiopatologia da Perturbação do Espetro do Autismo-Revisão Narrativa da Literatura. 36.

Fleury-Teixeira, P., Caixeta, F. V., Da Silva, L. C. R., Brasil-Neto, J. P., & Malcher-Lopes, R. (2019). Effects of cbd-enriched cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use. Frontiers in Neurology, 10(OCT), 1–9.

Howlett, A., Blume, L., & Dalton, G. (2010). CB1 Cannabinoid Receptors and their Associated Proteins. Current Medicinal Chemistry, 17(14), 1382–1393.

Karhson, D. S., Krasinska, K. M., Dallaire, J. A., Libove, R. A., Phillips, J. M., Chien, A. S., Garner, J. P., Hardan, A. Y., & Parker, K. J. (2018). Plasma anandamide concentrations are lower in children with autism spectrum disorder. Molecular Autism, 9(1), 1–6.

Lima, L. R., Alencar, G. S. B. C., Dutra, T. C. G., Bezerra, C. M. F. M. C., Lima, J. B., Gusmao, E. E. S., Costa, E. L., Silva, A. C. V., Trabulsi, R. K., Nicolau, A. D. M. F., Lopes, A. S. V., & New York, B. B. C. C. (2023). Avaliação dos benefícios do uso de canabidiol no tratamento de indivíduos com Transtorno do Espectro Autista (TEA). Brazilian Journal of Health Review, 6(4), 17665–17680.

MostafavI, M., & Gaitanis, J. (2020). Autism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience. Seminars in Pediatric Neurology, 35, 100833.

Oliveira, A. D. C., & Pottker, C. A. (2019). Considerações Sobre O Canabidiol No Processo Psicoterapêutico De Crianças Com Transtorno Do Espectro Autista. Revista UNINGÁ Review, 34(4), 24–37.

Oliveira, C. R.A., & Souza, J. C. (2021). Neurobiologia do autismo infantil. Research, Society and Development, 10(1), e11910111495.

Organización Pan-americana de la Salud - OPAS (2024, 08 de febrero).

Poleg, S., Golubchik, P., Offen, D., & Weizman, A. (2019). Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 89, 90–96.

Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Williams, S., Murphy, D. G. M., Daly, E., & Mcalonan, G. M. (2019). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 33(9), 1141–1148.

Silva, W. M., & Coelho, A. T. C. B. (2021). O processo de aquisiçao de linguagem para a criança com transtorno do espectro autista: artigo de revisão. Research, Society and Development, 10(1), e15010111584.

Wei, D., Lee, D. Y., Cox, C. D., Karsten, C. A., Penagarikano, O., Geschwind, D. H., Gall, C. M., & Piomelli, D. (2015). Endocannabinoid signaling mediates oxytocin-driven social reward. Proceedings of the National Academy of Sciences of the United States of America, 112(45), 14084–14089.

Zamberletti, E., Gabaglio, M., & Parolaro, D. (2017). The endocannabinoid system and autism spectrum disorders: Insights from animal models. International Journal of Molecular Sciences, 18(9), 1–14.



How to Cite

COLACITE, J.; CALIXTO, N. M. .; RECH, L. P. B. .; CAMPOS, L. S. .; FERREIRA, I. P. L. .; CUBAS FILHO, J. O. .; LEZAN, L. .; FLORENTIN, A. A. .; CASTANHO, P. B. .; OLIVEROS, C. A. . Use of cannabidiol in the treatment of autism, review of the literature and future perspectives. Research, Society and Development, [S. l.], v. 13, n. 3, p. e5113341741, 2024. DOI: 10.33448/rsd-v13i3.41741. Disponível em: Acesso em: 15 jun. 2024.



Health Sciences